inetetamab + gemcitabine + cisplatin

Inetetamab + gemcitabine + cisplatin is a combination regimen consisting of three agents with distinct mechanisms of action, used in oncology. Inetetamab is a novel anti-HER2 monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), exhibiting potent antibody-dependent cell-mediated cytotoxicity and inducing pyroptosis in HER2-positive cancer cells[1][2]. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, leading to apoptosis in rapidly dividing tumor cells[3][5]. Cisplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks and induces apoptosis by interfering with DNA replication and transcription[3][5]. The combination has shown synergistic antitumor effects, particularly in HER2-positive cancers such as lung adenocarcinoma and potentially other solid tumors. Inetetamab enhances immune-mediated killing of tumor cells when combined with chemotherapy agents like cisplatin; together they inhibit HER2/AKT/Nrf2 signaling, increase reactive oxygen species (ROS), and trigger NLRP3/caspase-1/GSDMB-mediated pyroptosis[1]. Gemcitabine plus cisplatin ("GC") is an established chemotherapy backbone for several cancers including non-small cell lung cancer, biliary tract cancer, gallbladder cancer, and breast cancer[3][5][6][7][8].